• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones.

作者信息

Ho P L, Yam W C, Que T L, Tsang D N, Seto W H, Ng T K, Ng W S

机构信息

Department of Microbiology, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.

出版信息

J Antimicrob Chemother. 2001 May;47(5):655-8. doi: 10.1093/jac/47.5.655.

DOI:10.1093/jac/47.5.655
PMID:11328779
Abstract

Ciprofloxacin-susceptible (n = 7) and -resistant (MIC >or=4 mg/L) (n = 15) clinical isolates of Streptococcus pneumoniae from diverse sources in Hong Kong were studied for target site modifications and efflux phenotype. Reserpine-inhibited efflux of ciprofloxacin and/or levofloxacin was common in both susceptible and non-susceptible isolates. The ParC substitutions K137N and/or S79F or Y were associated with increased ciprofloxacin MICS. The GyrA substitution S81F was only found in isolates with full resistance to ciprofloxacin (MIC >or=16 mg/L) and levofloxacin (MIC >or=8 mg/L). Among clinical isolates of S. pneumoniae, accumulation of target site mutations in strains with an efflux mechanism was associated with increasing MICs of fluoroquinolones.

摘要

相似文献

1
Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones.
J Antimicrob Chemother. 2001 May;47(5):655-8. doi: 10.1093/jac/47.5.655.
2
Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.野生型、外排阳性或含有ParC或GyrA突变的肺炎链球菌分离株的单步氟喹诺酮耐药突变体的突变预防浓度。
Antimicrob Agents Chemother. 2004 Oct;48(10):3954-8. doi: 10.1128/AAC.48.10.3954-3958.2004.
3
Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae.作为肺炎链球菌临床分离株喹诺酮耐药机制的外排作用和靶点突变
J Antimicrob Chemother. 2000 Apr;45 Suppl 1:95-9. doi: 10.1093/jac/45.suppl_3.95.
4
Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.氟喹诺酮类药物对耐环丙沙星肺炎链球菌的药效学活性
J Antimicrob Chemother. 2002 May;49(5):807-12. doi: 10.1093/jac/dkf022.
5
Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.肺炎链球菌对氟喹诺酮敏感的分离株真的敏感吗?1997年和2003年加拿大分离株耐药机制的比较。
J Antimicrob Chemother. 2005 Oct;56(4):769-72. doi: 10.1093/jac/dki315. Epub 2005 Aug 26.
6
Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae.肺炎链球菌氟喹诺酮耐药及敏感临床分离株中外排泵基因pmrA的表达
Antimicrob Agents Chemother. 2002 Mar;46(3):808-12. doi: 10.1128/AAC.46.3.808-812.2002.
7
Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin.肺炎链球菌临床分离株parC和gyrA基因突变与对环丙沙星和格帕沙星耐药性的关系。
J Med Microbiol. 1999 Dec;48(12):1103-1106. doi: 10.1099/00222615-48-12-1103.
8
Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.肺炎链球菌临床分离株中的氟喹诺酮耐药性:II型拓扑异构酶突变和外排对耐药水平的影响
Antimicrob Agents Chemother. 2000 Nov;44(11):3049-54. doi: 10.1128/AAC.44.11.3049-3054.2000.
9
In vitro activity of older and newer fluoroquinolones against efflux-mediated high-level ciprofloxacin-resistant Streptococcus pneumoniae.新旧氟喹诺酮类药物对由外排介导的高水平环丙沙星耐药肺炎链球菌的体外活性。
Int J Antimicrob Agents. 2004 Aug;24(2):185-7. doi: 10.1016/j.ijantimicag.2004.01.012.
10
Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy.意大利出现的对氟喹诺酮类药物敏感性降低的临床肺炎链球菌分离株的分子特征分析
Microb Drug Resist. 2004 Fall;10(3):209-17. doi: 10.1089/mdr.2004.10.209.

引用本文的文献

1
Fluoroquinolone and other antimicrobial resistance in invasive pneumococci, Hong Kong, 1995-2001.1995 - 2001年香港侵袭性肺炎球菌中的氟喹诺酮及其他抗菌药物耐药性
Emerg Infect Dis. 2004 Jul;10(7):1250-7. doi: 10.3201/eid1007.030612.
2
Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.加替沙星(BMS 284756)对1999年至2001年亚太地区SENTRY项目临床分离株的抗菌活性。
Antimicrob Agents Chemother. 2004 Jun;48(6):2049-55. doi: 10.1128/AAC.48.6.2049-2055.2004.
3
Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.
肺炎链球菌的抗菌药物敏感性断点及parC基因第一步突变:重新定义氟喹诺酮类耐药性
Emerg Infect Dis. 2003 Jul;9(7):833-7. doi: 10.3201/eid0907.020589.
4
Molecular characterization and antimicrobial susceptibility of fluoroquinolone-resistant or -susceptible Streptococcus pneumoniae from Hong Kong.香港耐氟喹诺酮或氟喹诺酮敏感肺炎链球菌的分子特征及抗菌药敏性
Antimicrob Agents Chemother. 2003 Apr;47(4):1433-5. doi: 10.1128/AAC.47.4.1433-1435.2003.